---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-022539"
form_type: "8-K"
ticker: "PASG"
cik: "0001787297"
company_name: "Passage BIO, Inc."
filed_at: "2026-03-03T23:59:59+00:00"
generated_at: "2026-05-15T22:19:04.866334+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Passage Bio reports 2025 net loss of $45.5M; cash runway through Q1 2027; advances FTD clinical program

## Summary
- Cash and cash equivalents $46.3M at Dec 31, 2025; funding expected through Q1 2027.
- Net loss of $45.5M ($14.35/diluted share) for 2025, improved from $64.8M ($21.04/sh) in 2024.
- R&D expenses $23.3M in 2025, down from $40.2M in 2024; G&A $19.9M vs $25.0M.
- Enrolled first 3 FTD-GRN patients in Cohort 3; dosed first FTD-C9orf72 patient with Dose 2 PBFT02 in Cohort 4.
- Expects interim safety/biomarker data and regulatory feedback on FTD-GRN registrational trial in 1H 2026.

## SEC filing metadata
- accession: 0001104659-26-022539
- form_type: 8-K
- ticker: PASG
- cik: 0001787297
- company_name: Passage BIO, Inc.
- filed_at: 2026-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787297/000110465926022539/0001104659-26-022539-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787297/000110465926022539/pasg-20260303x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-022539
- JSON: https://secwatch.observer/filing/0001104659-26-022539.json
- Plain text: https://secwatch.observer/filing/0001104659-26-022539.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.